Regeneron Pharmaceuticals (REGN) EPS (Weighted Average and Diluted) (2010 - 2026)
Regeneron Pharmaceuticals (REGN) recorded quarterly EPS (Weighted Average and Diluted) of $6.75 in Q1 2026, down 14.23% quarter-over-quarter from $7.87 in Q4 2025, and down 7.15% on a YoY basis from $7.27 in Q1 2025.
Regeneron Pharmaceuticals (REGN) EPS (Weighted Average and Diluted) (2010 - 2026) Analysis & Trends
Regeneron Pharmaceuticals' EPS (Weighted Average and Diluted) history runs 17 years deep, the most recent figure standing at $6.75 for Q1 2026.
- In Q1 2026, EPS (Weighted Average and Diluted) fell 7.15% year-over-year to $6.75; the TTM figure through Mar 2026 stood at $41.05 (up 4.37% YoY), while the FY2025 annual figure was $41.48, up 8.19% from the prior year.
- EPS (Weighted Average and Diluted) was $6.75 for Q1 2026 at Regeneron Pharmaceuticals, down from $7.87 in the prior quarter.
- In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $13.62 in Q3 2025 to a low of $6.27 in Q1 2024.
- Historically, EPS (Weighted Average and Diluted) has averaged $9.39 across 5 years, with a median of $8.61 in 2022.
- The sharpest annual moves came in 2022 and 2024: EPS (Weighted Average and Diluted) slumped 73.29% in 2022, then jumped 46.0% in 2024.
- A 5-year view of EPS (Weighted Average and Diluted) shows it stood at $10.49 in 2022, then decreased by 2.76% to $10.2 in 2023, then slipped by 20.49% to $8.11 in 2024, then decreased by 2.96% to $7.87 in 2025, then fell by 14.23% to $6.75 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at $6.75 (Q1 2026), $7.87 (Q4 2025), and $13.62 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.06 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 0.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -0.61 |
| 10 | Regeneron Pharmaceuticals | 63.43 Bn | 54.67 Bn | 3.31 Bn | 6.75 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.75 |
| Dec 31, 2025 | 7.87 |
| Sep 30, 2025 | 13.62 |
| Jun 30, 2025 | 12.81 |
| Mar 31, 2025 | 7.27 |
| Dec 31, 2024 | 8.11 |
| Sep 30, 2024 | 11.54 |
| Jun 30, 2024 | 12.41 |
| Mar 31, 2024 | 6.27 |
| Dec 31, 2023 | 10.20 |
| Sep 30, 2023 | 8.89 |
| Jun 30, 2023 | 8.50 |
| Mar 31, 2023 | 7.17 |
| Dec 31, 2022 | 10.49 |
| Sep 30, 2022 | 11.66 |
| Jun 30, 2022 | 7.47 |
| Mar 31, 2022 | 8.61 |
| Dec 31, 2021 | 19.68 |
| Sep 30, 2021 | 14.33 |
| Jun 30, 2021 | 27.97 |